RU2063752C1 - Medicinal agent for treatment of senile, diabetic and radiation sluggish wound - Google Patents

Abstract

FIELD: medicine. SUBSTANCE: 5-10% xymedone lanolin-vaselin-base ointment is applied on wound at the following ratio of components, wt.-%: xymedone 5-10; anhydrous lanolin 40-45; medicinal vaselin - the rest or 5-10% xymedone powder prepared on talc at the following ratio of components, wt.-%: xymedone 5-10; medicinal talc 90-95. Agent does not cause complications. EFFECT: enhanced effectiveness of agent. 3 cl

Description

 The invention relates to medicine, namely to the treatment of long-term non-healing wounds in people of old age, as well as suffering from senile diabetes, anemia, oncological diseases and patients exposed to radiation.

 Torpid treatment of the wound process in this group of patients is well known.

 Known tool for the treatment of non-healing wounds with the use of methyluracil ointment.

 However, methyluracil ointment has low therapeutic efficacy, which significantly lengthens the treatment time for patients with obtaining rough sedentary scars.

 Of the significant disadvantages of methyluracil it should be noted: it is slightly soluble in water (up to 0.9%), which does not allow to obtain highly concentrated medicinal compositions with high osmotic activity; lack of antimicrobial activity; mixing with wound secretion leads to inactivation of the drug; during sterilization, it loses its therapeutic activity and turns into a placebo.

 The basis of the invention was the task of creating a new, more effective drug for the treatment of senile, diabetic and radiation non-healing wounds.

 The proposed tool has antibacterial activity and, compared with the known drugs used, reduces the phases of hydration and dehydration of the wound process, reduces the duration of treatment of wounds.

 The problem was solved by the fact that the proposed drug containing the active substance and diluent. As the active substance, N- (β-hydroxyethyl-4,6-dimethyldihydropyrimidone-2) Ximedon was used.

Xymedon as a chemical compound is known and described in the literature. This is a crystalline powder from white to light pink in color with T 137.5-139.5 ^o C, soluble in water. Allowed by the pharmaceutical committee of the USSR Ministry of Health for use by adults as an anti-burn agent in the form of tablets.

 Preferred dosage forms in the treatment of wounds are ointment xymedon on a lanolin-vaseline basis in the following ratio, wt.

Xymedon 5 10
Anhydrous lanolin 40 45
Vaseline medical rest
Xymedon powder on talc in the following ratio of components, wt.

Xymedon 5 10
Talcum powder rest
Comparison with the drugs used 10% methyluracil ointment shows that the proposed drug is 80 times more active against Staphylococcus aureus, Escherichia coli.

 The proposed drug was subjected to clinical study.

 Treatment with the proposed method in the conditions of purulent surgical department was carried out 46 patients older than 60 years, suffering from long-term non-healing wounds. Of the total number of patients, 19 were between 75 and 80 years old. 21 suffered from diabetes, 14. Oncological diseases 14. The wound area was within 18-200 cm. The control group consisted of 50 similar patients treated with methyluracil ointment and methyluracil powder.

 A comparative evaluation of the treatment results in the experimental and control groups showed that in the experiment the healing processes proceeded much faster. Visual intensification of healing has been observed especially in people with diabetes. 3-4 days earlier, compared with the control, intense marginal epithelization appeared, granulations became bright red, fine-grained without signs of necrosis. Cytological studies of wound exudate indicated a sharp decrease and even complete disappearance of microorganisms with an increase in the number of polyblasts. The phagocytic activity of neutrophils increased. Histochemical studies showed a significant increase in the activity of enzymes, including hydrolytic (acid phosphatase) in the cellular elements of a wound defect. On the 21st day in the experiment, 19 patients started full wound healing, while the rest had successful autodermal plastic surgery (in the control, respectively, on the 28th in 10). In the control group, primary autodermoplasty was successful only in half of the cases.

 In the subgroups of the experimental group of patients treated with Ximedon ointment (26) and powder (20), there was no difference in the average length of hospital stay of patients. However, in patients treated with ointment, there was a more intense formation of fine-grained granulations, and in those treated with powder, epithelialization.

 The table shows the comparative results of the clinical course of the wound process, depending on the type of treatment.

 Example 1. Patient B. 76 years old, was admitted 10.09.90 to the clinic with a diagnosis of a long-term non-healing wound (15x20 cm) of the right thigh, diabetes mellitus. I got injured 3.5 months ago. She was treated in a hospital, was discharged with an unhealed wound, which began to increase during outpatient treatment, despite the use of 10% methyluracil ointment. Assigned to complex therapy with topical application of 10% ximedon ointment. On the 15th day, autothermoplasty was done with a dermatome flap, which completely took root. Home was discharged on the 30th day from the moment of receipt.

 Example 2. Patient W., 70 years old, diagnosis: extensive long-term non-healing wound of the anterior chest wall. 1.5 years ago, she was operated on for breast cancer followed by radiation therapy for incomplete wound healing. The latter periodically increased in size and the last 3 months has no tendency to decrease, despite intensive inpatient and outpatient treatment. Assigned to complex therapy. As a local stimulant, 10% xymedon powder was used. On the 22nd day, the wound healed completely with the formation of soft scar tissue.

 The proposed treatment for senile, diabetic and radiation non-healing wounds has significant advantages over the prototype: it has antibacterial activity; the phases of hydration and dehydration of the wound process are reduced; wound healing time is reduced.

 Thus, the local use of 10% xymedonic ointment and powder in the complex treatment of elderly patients, as well as those suffering from diabetes and oncological diseases, leads to a change in the size of the wound, accelerate its healing and shorten the treatment time for patients.

 There were no complications with topical use of 5-10% xymedon ointment, powder in the experiment and in the clinic.

 In acute and chronic experience, xymedon ointment and powder does not have an allergenic and para-allergenic local irritant effect on the body. TTT1

Claims (2)

 1. A medicine for the treatment of senile, diabetic and radiation-induced non-healing wounds, containing an active and base-forming agent, characterized in that it contains N - (β-hydroxyethyl) -4,6-dimethyldihydropyrimidone-Z as an active agent base vaseline-lanolin mixture with a ratio of components, wt. N- (b-hydroxyethyl) -4,6-dimethyldihydropyrimidone-2 5-10, anhydrous lanolin 40-45, medical rest petroleum jelly.  2. A medicine for the treatment of senile, diabetic and radiation-resistant non-healing wounds, containing an active agent and an excipient, characterized in that it contains N - (b-hydroxyethyl) -4,6-dimethyldihydropyrimidone-2 as an active agent, and in as a filler, talc with a ratio of components (wt.): N - (b-hydroxyethyl) -4,6-dimethyldihydropyrimidone-2 5-10, talc the rest.

Images